API

Active Pharmaceutical Ingredients (API), popularly speaking, are the raw materials of medicines, only pharmaceutical raw materials are processed into pharmaceutical preparations , can they become medicines available for clinical use, so drugs we usually eat are the finished drugs through processing. Active Pharmaceutical Ingredients based on its sources can be divided into two major categories ,including chemical synthetic drugs and natural chemical drugs. Chemical synthetic drugs can be divided into organic synthetic drugs and inorganic synthetic drugs. Inorganic synthetic drugs are inorganic compounds ( very few is element), such as aluminum hydroxide, magnesium trisilicate which are used for the treatment of gastric and duodenal ulcers ; organic synthetic drugs are mainly composed of drugs made by basic organic chemical raw materials, through a series of organic chemical reactions (such as aspirin, chloramphenicol, caffeine, etc.). Natural chemical drugs ,based on its sources,can be divided into two categories including biochemical drugs and plant chemical drugs. Antibiotics are generally made by the microbial fermentation, which belongs to the biochemistry category. A variety of semi-synthetic antibiotics occurs in recent years,which are biosynthesis and chemical synthesis combining products.Among active Pharmaceutical Ingredients, the organic synthetic drugs varieties, yields and values have the largest proportion,which are the main pillars of the chemical and pharmaceutical industries. The quality of active Pharmaceutical Ingredients decides whether the formulation is good or bad , so its quality standards are very strict ,countries in the world have developed national pharmacopoeia standards and strict quality control methods for its widely used active Pharmaceutical ingredients.

Tetrahydro-4H-pyran-4-one: Synthesis and Potential Pharmaceutical Applications

Tetrahydro-4H-pyran-4-one is synthesized using various reagents and solvents, and has pharmaceutical applications as an SSAO inhibitor and a modulator of NMDA receptors.

Jan 9,2024  API

Acyclovir: Antiviral Medication for Herpes with Promising Pharmacokinetics and Potency

Acyclovir treats viral infections. Oral absorption is limited with peak plasma concentrations of 0.5 μg/ml. Dosages vary by indication.

Jan 9,2024  API

Cinnamic Acid: Dietary Sources, Mechanisms of Action and New Formulation

Cinnamic acid in plant-based foods stimulates insulin secretion, but its limited bioavailability led to new formulations like nanoparticles for improved effectiveness against chronic diseases.

Jan 9,2024  API

Understanding the Mechanism, Pharmacokinetics, and Side Effects of Prednisolone

Prednisolone binds to glucocorticoid receptors, with 70% bioavailability. Metabolism involves prednisone conversion. Overdose causes side effects.

Jan 9,2024  API

Zinc Pyrithione: A Promising Anti-Fungal Compound for Dermatologic Applications

Zinc Pyrithione has high skin permeability and exhibits anti-fungal activity against Malassezia yeast, commonly used in medicated shampoos for treating dandruff and seborrheic dermatitis.

Jan 9,2024  API

Agar-based edible films for food packaging applications

Agar can create edible films with gelling ability. Adding components like plasticizers and biopolymers improves flexibility and functional properties, expanding applications.

Jan 9,2024  API

A first-in-class potent 5-HT2A antagonist: Lumateperone

Lumateperone, also known as ITI-007, is a first-in-class potent 5-HT2A antagonist, postsynaptic D2 antagonist, and inhibitor of serotonin transport developed by Intra-Cellular Therapies under a licens

Jan 8,2024  API

The synthesis method of Lemborexant

Lemborexant is an orally administered dual orexin receptor (OXR) antagonist developed by Eisai for the treatment of adults with insomnia.

Jan 8,2024  API

How Lasmiditan works in treating migraine

Lasmiditan, or COL-144, is an orally bioavailable selective serotonin receptor agonist (SSRA) discovered by Eli Lilly and Company and licensed to CoLucid Pharmaceuticals before Eli Lilly acquired CoLu

Jan 8,2024  API

How to synthesize Brexanolone?

Developed by Sage Therapeutics, brexanolone was approved by the USFDA as a first-in-class treatment for PPD in adult women.

Jan 8,2024  API
Prev12345678910...Next>  Go to Page